A share price of Dyne Therapeutics Inc [DYN] is currently trading at $25.83, up 2.05%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DYN shares have gain 3.40% over the last week, with a monthly amount drifted -7.22%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on April 30, 2024, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $40. Previously, H.C. Wainwright started tracking the stock with Buy rating on February 20, 2024, and set its price target to $36. On February 27, 2023, upgrade upgraded it’s rating to Strong Buy and revised its price target to $27 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $34 on February 15, 2023. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on January 26, 2023. Chardan Capital Markets started tracking with a Buy rating for this stock on July 20, 2022, and assigned it a price target of $17. In a note dated July 12, 2022, Raymond James initiated an Outperform rating and provided a target price of $15 on this stock.
Dyne Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.40 and $30.27. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $25.83 at the most recent close of the market. An investor can expect a potential return of 4.53% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.35% with Operating Profit Margin at -63.93%, Pretax Profit Margin comes in at -62.29%, and Net Profit Margin reading is -61.84%. To continue investigating profitability, this company’s Return on Assets is posted at -1.42, Equity is -1.35 and Total Capital is -2.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.93 points at the first support level, and at 24.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.01, and for the 2nd resistance point, it is at 28.19.
Dyne Therapeutics Inc [DYN] reported earnings per share of -$1.09 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.92/share, meaning a difference of -$0.17 and a surprise factor of -18.50%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.99 per share as compared to estimates of -$0.83 per share, a difference of -$0.16 representing a surprise of -19.30%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dyne Therapeutics Inc [NASDAQ:DYN] is 2.53. In addition, the Quick Ratio stands at 2.53 and the Cash Ratio stands at 2.38.
Transactions by insiders
Recent insider trading involved Farwell Wildon, Chief Medical Officer, that happened on Mar 12 ’24 when 1030.0 shares were sold. CEO & President, Brumm Joshua T completed a deal on Mar 11 ’24 to sell 66387.0 shares. Meanwhile, Chief Business Officer McNeill Jonathan sold 19601.0 shares on Mar 11 ’24.
